Hepathrombin

Hepathrombin is a pharmaceutical product that contains the anticoagulant heparin sodium as its active ingredient. It is supplied in a cutaneous dosage form, with the specific strength not disclosed in the available data, and is marketed within the European Union. As a member of the antithrombotic drug class, Hepathrombin works by enhancing antithrombin III activity to inhibit clotting factors IIa and Xa, helping to prevent and treat thromboembolic conditions.

Hepathrombin is indicated for several clinical situations where inhibition of blood clot formation is required.

- Prevention of deep vein thrombosis (DVT) in patients at risk. - Treatment of acute DVT to reduce clot propagation. - Management of pulmonary embolism (PE) to restore pulmonary perfusion. - Prevention and treatment of superficial thrombophlebitis. - Prophylaxis of thromboembolic events in surgical or immobilized patients.

The safety profile of Hepathrombin reflects the typical effects observed with heparin sodium, ranging from mild, frequently reported reactions to rare but serious complications.

Common: - Injection site erythema or pain. - Minor bruising or hematoma at the application site. - Nausea or mild gastrointestinal discomfort. - Transient elevation of liver enzymes.

Serious: - Heparin‑induced thrombocytopenia (HIT). - Major bleeding, including intracranial or gastrointestinal hemorrhage. - Spontaneous spinal or epidural hematoma. - Allergic anaphylaxis or severe hypersensitivity reaction.

When prescribing or using Hepathrombin, clinicians should consider several precautionary measures to minimize risk and ensure appropriate therapy.

- Assess baseline platelet count and coagulation parameters before initiation. - Monitor for signs of bleeding during treatment. - Use reduced doses in patients with renal or hepatic impairment. - Avoid use in individuals with known hypersensitivity to heparin or pork‑derived products. - Consider pregnancy status; data are limited, so weigh risks and benefits. - Review concomitant antiplatelet or anticoagulant therapy to prevent over‑anticoagulation.

Hepathrombin can interact with other medicines, affecting anticoagulant activity or bleeding risk.

Avoid: - Concurrent use of other anticoagulants (e.g., warfarin, direct oral anticoagulants) without dose adjustment. - Administration with thrombolytic agents (e.g., alteplase) due to additive bleeding risk. - Use with high‑dose aspirin or NSAIDs that impair platelet function.

Use with caution: - Combination with antiplatelet drugs (e.g., clopidogrel) may increase bleeding; monitor closely. - Concomitant use of certain antibiotics (e.g., quinolones) that may potentiate anticoagulant effect. - Co‑administration with corticosteroids may increase risk of gastrointestinal bleeding.